Real-world Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): IONA-MM First Interim Analysis

被引：0
|
作者：
Schwarzer, A. [1 ]
Schulte, C. [2 ]
Fries, S. [3 ]
Cavo, M. [4 ]
Tsukada, N. [5 ]
Tekle, C. [6 ]
Manasanch, E. E. [7 ]
Knauf, W. [8 ]
机构：
[1] Onkopraxis Probstheida, Leipzig, Germany
[2] Gemeinsch Praxis Hamatol & Onkol, Dortmund, Germany
[3] Onkol Schwerpunktpraxis, Bamberg, Germany
[4] Univ Bologna, IRCCS Azienda Osped, Ist Ematol, Bologna, Italy
[5] Japanese Red Cross Med Ctr, Div Hematol, Tokyo, Japan
[6] Sanofi, Cambridge, MA USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
[8] Centrum Hamatol & Onkol Bethanien, Frankfurt, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1109
引用
收藏
页码：316 / 316
页数：1
相关论文
共 50 条
  • [1] Real-world experience with isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM): IONA-MM first interim analysis
    Martin, Thomas
    Beksac, Meral
    Cavo, Michele
    Knauf, Wolfgang
    Tsukada, Nobuhiro
    Tekle, Christina
    Zhao, Zhenming
    Manasanch, Elisabet
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S178 - S178
  • [2] Real-world Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): IONA-MM First Interim Analysis
    Thomas, Martin
    Meral, Beksac
    Michele, Cavo
    Wolfgang, Knauf
    Nobuhiro, Tsukuda
    Christina, Tekle
    Zhenming, Zhao
    Manasanch, Elisabet E.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S27 - S27
  • [3] Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis
    Gaballa, Mahmoud R.
    Martin, Thomas G.
    Tsukada, Nobuhiro
    Suzuki, Kazuhito
    Iriuchishima, Hirono
    Chalayer, Emilie
    Camus, Vincent
    Pena, Maria Magdalena Alcala
    Furlan, Anna
    Hubmann, Max Christian Georg
    Knauf, Wolfgang Ulrich
    Tekle, Christina
    Minasyan, Ani
    Qiu, Chunfu
    Beksac, Meral
    BLOOD, 2024, 144 : 24115 - 24116
  • [4] Real-World Experience With Isatuximab (Isa) in Patients With Relapsed and/or Refractory Multiple Myeloma: IONA-MM First Interim Analysis
    Manasanch, Elisabet E.
    Beksac, Meral
    Cavo, Michele
    Knauf, Wolfgang
    Tsukada, Nobuhiro
    Tekle, Christina
    Zhao, Zhenming
    Martin, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S405 - S406
  • [5] IONA-MM: A prospective, non-interventional, multinational, observational study with isatuximab in patients with relapsed/refractory multiple myeloma (RRMM)
    Knauf, W.
    Tekle, C.
    Barnes, Y.
    Sievert, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 183 - 183
  • [6] IONA-MM: A Prospective, Non-Interventional, Multinational, Observational Study with Isatuximab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Tekle, Christina
    Barnes, Yvonne
    Sievert, Mark
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S296 - S297
  • [7] REAL-WORLD EXPERIENCE OF LENALIDOMIDE/DEXAMETHASONE TREATMENT FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM) PATIENTS
    Tognazzi, L.
    Rivolti, E.
    Quaresima, M.
    Labbozzetta, S.
    Gamberi, B.
    Merli, F.
    HAEMATOLOGICA, 2017, 102 : 137 - 137
  • [8] First clinical Experience of Isatuximab Safety and Tolerability in relapsed and refractory Multiple Myeloma (RRMM): Real-world Data from a Compassionate Use Program in Germany
    Salwender, H.
    Wendelin, K.
    Oduncu, F.
    Kimmich, C.
    Naumann, R.
    Kull, M.
    Goldschmidt, H.
    Ehmer, M.
    Brand, F.
    Kiewitz, C.
    Khandanpour, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 315 - 316
  • [9] Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Popat, Rakesh
    Martinez-Lopez, Joaquin
    Kastritis, Efstathios
    Brunaldi, Larissa
    Bansal, Radhika
    Corraes, Andre De Menezes Silva
    Yong, Kwee
    Mactier, Catriona
    Corona, Magdalena
    Saez Marin, Adolfo Jesus
    Fotiou, Despina
    Dimopoulos, Meletios Athanasios
    Chhabra, Saurabh
    Ailawadhi, Sikander
    Parrondo, Ricardo
    Martin, Thomas
    Durie, Brian G. M.
    Lin, Yi
    BLOOD, 2023, 142
  • [10] DURATION OF THERAPY IN US PATIENTS TREATED FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE REAL-WORLD
    Romanus, D.
    Raju, A.
    Yong, C.
    Seal, B.
    Farrelly, E.
    Noga, S.
    Jhaveri, M.
    Labotka, R.
    Blazer, M.
    Parameswaran, H.
    HAEMATOLOGICA, 2016, 101 : 538 - 539
12345